PHARMEASY UNLISTED SHARE PRICE (Updated 2025)

Get access to PharmEasy (API Holdings Limited) – India’s leading online pharmacy and digital healthcare platform. Market Cap: ₹4,220 Crore. 52-Week High: ₹10.50. 52-Week Low: ₹6.75.

About PharmEasy (API Holdings Limited)

PharmEasy, operating under API Holdings Limited, is India’s largest digital pharmacy and online healthcare platform providing affordable and accessible healthcare services to millions of customers. Founded in 2015, PharmEasy has revolutionized healthcare delivery through technology-enabled solutions.

Key Highlights:

• Founded: 2015
• Headquarters: Mumbai, Maharashtra, India
• Business Model: Digital pharmacy and healthcare e-commerce
• Market Position: India’s leading online pharmacy platform
• CIN: U67120HR2005PLC036952
• ISIN: INE0DJ201029
• Face Value: ₹1 per share
• Services: Online pharmacy, lab tests, telehealth consultations
• Acquisitions: Thyrocare merger for diagnostic services expansion

Financial Information (As of Latest Update)

Why Invest in PharmEasy Unlisted Shares?

• Healthcare Revolution: Part of India’s digital healthcare transformation
• Market Leadership: Dominant player in online pharmacy segment
• Growth Potential: Expanding diagnostic and telehealth services
• Large Addressable Market: Taps into India’s rising healthcare spending
• Tech-Enabled Platform: Scalable business model with high margins
• Strategic Acquisitions: Thyrocare integration adds diagnostics
• IPO Opportunity: Company planning to revisit IPO in 2025

How to Buy PharmEasy Unlisted Shares

1. Contact an unlisted share broker or dealer
2. Submit KYC documents: PAN card, Aadhaar, Demat account details
3. Verify current pricing and available quantity
4. Complete payment via bank transfer
5. Receive shares in your Demat account

• Required Documents:
  • PAN card
  • Aadhaar card
  • Demat account details (NSDL/CDSL)
  • Cancelled cheque or bank statement

Analyst View & Investment Risks

Positive Factors:

• Large market opportunity in digital healthcare
• Market leader in online pharmacy space
• Diversified revenue streams from multiple services
• Strong customer base and brand recognition
• Thyrocare integration adds diagnostics capability

Risk Factors:

• Recent Losses: Company facing profitability challenges
• Price Volatility: Share price declined significantly from earlier valuations
• IPO Uncertainty: Previous IPO withdrawal created investor sentiment issues
• Regulatory Risk: Subject to healthcare and e-commerce regulations
• Competition: Intense competition from other online pharmacies
• Cash Burn: High cash burn rate impacting financial health
• Lower Liquidity: Unlisted shares harder to sell than listed stocks

Frequently Asked Questions

What is PharmEasy’s core business?

PharmEasy operates as a digital pharmacy and healthcare platform providing medicine delivery, diagnostic tests, telehealth consultations, and health products.

Why has PharmEasy’s share price declined so much?

The significant decline (from ₹105 to ₹6.50) is due to persistent losses, regulatory challenges, and delayed IPO plans affecting investor sentiment.

Is PharmEasy currently profitable?

No, PharmEasy has been facing operational losses. The company reported a net loss of around ₹15,168 crore for recent fiscal year.

When is PharmEasy’s IPO expected?

PharmEasy is planning to revisit IPO plans and is expected to file fresh DRHP with SEBI. Timing remains uncertain due to regulatory considerations.

Disclaimer:

Investments are subject to market risks. This information is for educational purposes only. Please consult a registered financial advisor before investing. PharmEasy shares carry higher risk due to current profitability challenges.